natgillin/translations-raw huggingface dataset:
In vitro binding of lenvatinib to human plasma proteins is high and ranged from 98% to 99% (0.3 - 30 μg/mL, mesylate). 
Vezava lenvatiniba na beljakovine humane plazme in vitro je velika, v razponu od 98 % do 99 % (0,3-30 μg/ml, mesilat).
Lenvatinib exhibited good oral bioavailability in dogs (70.4%) and monkeys (78.4%). 
Lenvatinib je pokazal dobro peroralno biološko uporabnost pri psih (70,4 %) in opicah
• severe pain in your belly (abdomen) - this may be due to a hole in the wall of your gut or a fistula (a hole in your gut which links through a tube-like passage to another part of your body or skin). 
• močna bolečina v trebuhu (abdomnu) - ta lahko nastane zaradi luknje v steni črevesa ali fistule (luknja v črevesu, ki je po cevastem prehodu povezana z drugim delom vašega telesa ali kožo);
Dose adjustments and Discontinuation for HCC 
Prilagajanje odmerka in ukinitev pri HCC
Appropriate measures should be taken to control blood pressure (see section 4.4, Hypertension). 
Uvesti je treba primerne ukrepe za obvladanje krvnega tlaka (glejte poglavje 4.4 Hipertenzija).
The primary risk factor identified was dehydration and/or hypovolemia due to gastrointestinal toxicity. 
Ugotovili so, da je bil primarni dejavnik tveganja dehidracija in/ali hipovolemija zaradi toksičnosti za prebavila.
The hepatic failure cases were generally reported in patients with progressive metastatic liver metastases disease. 
O primerih odpovedi jeter so na splošno poročali pri bolnikih s progresivno metastatsko jetrno boleznijo.
Polyamide/Aluminium/PVC/Aluminium blisters containing 10 capsules. 
Pretisni omoti iz poliamida/aluminija/PVC/aluminija, ki vsebujejo po 10 kapsul.
Adverse reactions observed in clinical trials in DTC and HCC and reported from post-marketing use of lenvatinib are listed in Table 5. 
Neželeni učinki, ki so jih ugotovili v kliničnih preskušanjih pri DTC in HCC ter o katerih so poročali pri uporabi lenvatiniba v obdobju trženja, so navedeni v preglednici 5.
Haematologic toxicity or proteinuria-no dose adjustment required for first occurrence. 
Hematološka toksičnost ali proteinurija: pri prvem pojavu prilagajanje odmerka ni potrebno.
Manufacturer Eisai Manufacturing Ltd, Mosquito Way, Hatfield, Herts AL10 9SN, United Kingdom. 
Proizvajalec Eisai Manufacturing Ltd, Mosquito Way, Hatfield, Herts AL10 9SN, Velika Britanija.
• Caregivers should not open the capsules to avoid exposure to the contents of the capsule. 
• Skrbniki bolnikov naj ne odpirajo kapsul, da ne bodo prišli v stik z vsebino kapsule.
Patients with end-stage renal disease were not studied, therefore the use of lenvatinib in these patients is not recommended. 
Bolnikov z boleznijo ledvic v končnem stadiju niso proučevali, zato uporaba lenvatiniba pri teh bolnikih ni priporočljiva.
The positive effect on PFS was seen across the subgroups of age (above or below 65 years), sex, race, histological subtype, geographic region, and those who received 0 or 1 prior VEGF/VEGFR-targeted therapies. 
Pozitivni učinek na PFS je bil viden v podskupinah po starosti (več ali manj kot 65 let), spolu, rasi, histološki podvrsti, zemljepisni regiji in tistih, ki so prejeli 0 ali 1 predhodna zdravljenja, usmerjena v VEGF/VEGFR.
Mild to severe hypertension may be present. 
Lahko je prisotna blaga do huda hipertenzija.
Reduce dose in succession based on the previous dose level (12 mg, 8 mg, 4 mg or 4 mg every other day). 
Odmerek zmanjšajte v korakih glede na predhodni odmerek (12 mg, 8 mg, 4 mg ali 4 mg vsak drugi dan).
Symptoms and Management 
Simptomi in zdravljenje
The overall survival analysis was confounded by the fact that placebo-treated subjects with confirmed disease progression had the option to cross over to open-label lenvatinib. 
Analizo celotnega preživetja je otežilo dejstvo, da so preiskovanci s potrjenim napredovanjem bolezni, ki so prejemali placebo, imeli možnost izbire prehoda na odprti lenvatinib.
In vitro transporter studies 
Študije prenašalcev in vitro
LENVIMA can also be used on its own to treat liver cancer (hepatocellular carcinoma) in adults who have not previously been treated with another anticancer medicine that travels through the bloodstream. 
Zdravilo LENVIMA se lahko uporablja tudi za samostojno zdravljenje raka jeter (hepatocelularnega karcinoma) pri odraslih, ki še niso bili zdravljeni z drugim zdravilom proti raku, ki potuje po krvnem obtoku.
A risk to newborns or infants cannot be excluded and, therefore, lenvatinib is contraindicated during breast-feeding (see section 4.3). 
Tveganja za novorojenčke ali dojenčke ni mogoče izključiti, zato je lenvatinib med dojenjem kontraindiciran (glejte poglavje 4.3).
In 1.1% of patients, hypertension led to permanent treatment discontinuation. 
Pri 1,1 % bolnikov je hipertenzija povzročila trajno ukinitev zdravljenja.
P-value is for the superiority test of lenvatinib versus sorafenib. 
d Vrednost p velja za preskus superiornosti lenvatiniba v primerjavi s sorafenibom.
Lenvatinib is a multikinase inhibitor which has shown mainly antiangiogenic properties in vitro and in vivo, and direct inhibition of tumour growth was also observed in in vitro models. 
Lenvatinib je multikinazni inhibitor, ki je in vitro in in vivo pokazal predvsem antiangiogene lastnosti, v modelih in vitro pa so opazili tudi neposredno inhibicijo rasti tumorjev.
• Absence of MPVI, extra-hepatic tumour spread (EHS) or both: 30% 
• odsotnost MPVI, razširjenost tumorja izven jeter (EHS - extra-hepatic tumour spread) ali oboje:
Hepatic encephalopathy occurred at more than twice the incidence in patients aged ≥75 years (17.2%) than in those <75 years (7.1%). 
Jetrna encefalopatija se je pojavila več kot dvakrat pogosteje pri bolnikih, starih ≥ 75 let (17,2 %), kot pri bolnikih, starih < 75 let (7,1 %).
Lenvatinib should be discontinued in the event of persistence of Grade 4 diarrhoea despite medical management. 
Lenvatinib je treba ukiniti v primeru driske stopnje 4, ki vztraja kljub medicinski obravnavi.
• anal fistula (a small channel that forms between the anus and the surrounding skin) 
• analna fistula (majhen kanal, ki nastane med zadnjikom in okolno kožo),
There have also been reports of overdose with lenvatinib involving single administrations of 6 to 10 times the recommended daily dose. 
Poročali so tudi o prevelikem odmerjanju lenvatiniba, kjer so bili enkratni odmerki 6-krat do 10-krat večji od priporočenega dnevnega odmerka.
Lenvatinib showed minimal or no inhibitory effect on OATP1B3 and MATE2-K. Lenvatinib weakly inhibits MATE1. 
Lenvatinib je pokazal minimalen ali nikakršen inhibicijski učinek na OATP1B3 in MATE2-K. Lenvatinib šibko inhibira MATE1.
Close monitoring of overall safety is recommended in these patients (see sections 4.4 and 5.2). 
Pri teh bolnikih je priporočljivo natančno spremljanje celotne varnosti (glejte poglavji 4.4 in 5.2).
Lenvatinib should be withheld in the event of development of QT interval prolongation greater than 500 ms. Lenvatinib should be resumed at a reduced dose when QTc prolongation is resolved to < 480 ms or baseline. 
Dajanje lenvatiniba je treba prekiniti, če se razvije podaljšanje intervala QT, ki presega 500 ms. Lenvatinib je treba spet začeti dajati v zmanjšanem odmerku, ko se podaljšanje intervala QTc vrne na < 480 ms ali izhodiščno vrednost.
Electrolytes (magnesium, potassium and calcium) should be monitored periodically during treatment. 
Med zdravljenjem je treba v rednih časovnih presledkih spremljati elektrolite (magnezij, kalij in kalcij).
Blood calcium levels should be monitored at least monthly and calcium should be replaced as necessary during lenvatinib treatment. 
Raven kalcija v krvi je treba spremljati vsaj enkrat na mesec in med zdravljenjem z lenvatinibom kalcij po potrebi nadomeščati.
LENVIMA treatment should be initiated and supervised by a health care professional experienced in the use of anticancer therapies. 
Zdravljenje z zdravilom LENVIMA mora uvesti in nadzorovati zdravnik z izkušnjami pri uporabi zdravil proti raku.
• other types of fistulae (an abnormal connection between different organs in the body or between the skin and an underlying structure such as throat and windpipe). 
• druge vrste fistul (fistula je nenormalna povezava med različnimi telesnimi organi ali med kožo in spodaj ležečo strukturo, na primer žrelom in sapnikom).
• If you have or have had an aneurysm (enlargement and weakening of a blood vessel wall) or a tear in a blood vessel wall. 
• imate ali ste imeli anevrizmo (razširitev in oslabitev stene krvne žile) ali raztrganino v steni krvne žile.
Prompt medical management of diarrhoea should be instituted in order to prevent dehydration. 
Začeti moramo takojšnjo medicinsko obravnavo driske, da preprečimo dehidracijo.
Systolic BP ≥140 mmHg up to <160 mmHg or diastolic BP ≥90 mmHg up to <100 mmHg 
Priporočeno ukrepanje sistolični KT ≥ 140 mmHg do < 160 mmHg ali diastolični KT ≥ 90 mmHg do < 100 mmHg
Systolic BP ≥160 mmHg or diastolic BP ≥100 mmHg despite optimal antihypertensive therapy 
sistolični KT ≥ 160 mmHg ali diastolični KT ≥ 100 mmHg kljub optimalni antihipertenzivni terapiji
M2' and M3', the major metabolites in human faeces, were formed from M2 and lenvatinib, respectively, by aldehyde oxidase. 
M2' in M3', poglavitna presnovka v človeškem blatu, sta nastala iz M2 oziroma lenvatiniba z aldehidno oksidazo.
The clinical efficacy and safety of lenvatinib have been evaluated in an international, multicenter, open-label, randomised phase 3 study (REFLECT) in patients with unresectable hepatocellular carcinoma (HCC). 
Klinična učinkovitost in varnost lenvatiniba sta bili ocenjeni v mednarodni multicentrični odprti randomizirani študiji 3. faze (REFLECT) pri bolnikih z neoperabilnim hepatocelularnim karcinomom (HCC).
Therefore, the decision to resume lenvatinib following a major surgical procedure should be based on clinical judgment of adequate wound healing. 
Odločitev za nadaljevanje zdravljenja z lenvatinibom po večjem kirurškem posegu mora zato temeljiti na klinični presoji, ali se rane primerno celijo.
Percentages (95% CI) 
Odstotki (95-odstotni IZ)
Cases of fatal intracranial haemorrhage have been reported in some patients with or without brain metastases. 
O primerih smrtnih znotrajlobanjskih krvavitev so poročali pri nekaterih bolnikih z zasevki v možganih ali brez njih.
• The active substance is lenvatinib. 
• Učinkovina je lenvatinib.
• If you have severe liver or kidney problems the recommended dose is 14 mg once a day 
• Če imate izrazite težave z jetri ali ledvicami, je priporočeni odmerek 14 mg enkrat na dan
PHARMACEUTICAL FORM AND CONTENTS 30 hard capsules 60 hard capsules 90 hard capsules METHOD AND ROUTE(S) OF ADMINISTRATION Oral use. 
FARMACEVTSKA OBLIKA IN VSEBINA 30 trdih kapsul 60 trdih kapsul 90 trdih kapsul POSTOPEK IN POT(I) UPORABE ZDRAVILA Peroralna uporaba.
In addition, pneumothorax has been reported with and without clear evidence of a bronchopleural fistula. 
Poleg tega so poročali o pnevmotoraksu, z jasnimi dokazi bronhoplevralne fistule in brez njih.
Details for monitoring, dose adjustment and discontinuation are provided in Table 2. 
Podrobni podatki za spremljanje, prilagoditev odmerka in ukinitev zdravljenja so v preglednici 2.
Resolves to Grade 0-1. 
Izboljša se na stopnjo 0-1
To dissolve them, pour a tablespoon of water or apple juice into a small glass and put the capsules into the liquid without breaking or crushing them. 
Za raztapljanje nalijte jedilno žlico vode ali jabolčnega soka v majhen kozarec ter kapsule dodajte v tekočino, ne da bi jih prelomili ali zdrobili.
The median half-life was comparable in subjects with mild, moderate, and severe hepatic impairment as well as those with normal hepatic function and ranged from 26 hours to 31 hours. 
Mediana razpolovna doba je bila primerljiva pri preiskovancih z blago, zmerno in hudo okvaro jeter, pa tudi pri tistih z normalno funkcijo jeter, in je bila v razponu od 26 ur do 31 ur.
• diarrhoea, feeling and being sick - these are very common side effects that can become serious if they cause you to become dehydrated, which can lead to kidney failure. 
• driska, slabost in bruhanje - to so zelo pogosti neželeni učinki, ki lahko postanejo resni, če zaradi njih postanete dehidrirani, kar lahko povzroči odpoved ledvic.
• low levels of platelets in the blood which may lead to bruising and difficulty in wound healing 
• nizka koncentracija krvnih ploščic v krvi, ki lahko povzroči modrice in oteženo celjenje ran.
Pharmacotherapeutic group: antineoplastic agents, protein kinase inhibitors, ATC code: L01XE29 
Farmakoterapevtska skupina: zdravila z delovanjem na novotvorbe (citostatiki), inhibitorji proteinske kinaze, oznaka ATC: L01XE29.
• black, tarry, or bloody stools, or coughing up of blood - these may be signs of bleeding inside your body. 
• črno, katranasto ali krvavo blato ali izkašljevanje krvi - to so lahko znaki krvavitve znotraj telesa;
Electrocardiograms should be monitored at baseline and periodically during treatment in all patients with particular attention to those with congenital long QT syndrome, congestive heart failure, bradyarrhythmias, and those taking medicinal products known to prolong the QT interval, including Class Ia and III antiarrhythmics. 
Elektrokardiograme je treba spremljati v izhodišču in v rednih presledkih ves čas zdravljenja pri vseh bolnikih, posebno pa moramo biti pozorni na tiste s prirojenim sindromom dolgega intervala QT, kongestivnim popuščanjem srca, z bradiaritmijami in pri tistih, ki jemljejo zdravila, za katera je znano, da podaljšujejo interval QT, vključno z antiaritmiki skupin Ia in III.
The degree of tumour invasion/infiltration of major blood vessels (e.g. carotid artery) should be considered because of the potential risk of severe haemorrhage associated with tumour shrinkage/necrosis following lenvatinib therapy. 
Treba je oceniti stopnjo tumorske invazije/infiltracije večjih krvnih žil (npr. karotidnih arterij) zaradi možnega tveganja resne krvavitve, povezane z zmanjšanjem tumorske mase/nekrozo tumorja po zdravljenju z lenvatinibom.
• are a woman able to become pregnant (see the section below on Contraception, pregnancy and breast-feeding) 
• ste ženska, ki bi lahko zanosila (glejte poglavje Kontracepcija, nosečnost in dojenje v nadaljevanju);
• The recommended dose of LENVIMA is usually 24 mg once a day 
• Priporočeni odmerek zdravila LENVIMA je navadno 24 mg enkrat na dan
Caregivers should not open the capsule, in order to avoid repeated exposure to the contents of the capsule. 
Skrbniki bolnikov naj ne odpirajo kapsul, da se bodo izognili večkratnemu izpostavljanju vsebini kapsul.
People get LENVIMA when their liver cancer has spread or cannot be taken out by surgery. 
Bolniki prejmejo zdravilo LENVIMA, če se je rak jeter razširil ali ga s kirurškim posegom ni mogoče odstraniti.
Drink the mixture. 
Suspenzijo spijte.
Leave for at least 10 minutes then stir for at least 3 minutes to dissolve the capsule shells. 
Pustite jih v tekočini vsaj 10 minut, nato mešajte vsaj 3 minute, da se ovojnica kapsule raztopi.
What you need to know before you take LENVIMA 
Kaj morate vedeti, preden boste vzeli zdravilo LENVIMA
It is not known whether lenvatinib is excreted in human milk. 
Ni znano, ali se lenvatinib izloča v materino mleko.
Do not take LENVIMA if: 
Ne jemljite zdravila LENVIMA:
In patients with solid tumours administered single and multiple doses of lenvatinib once daily, exposure to lenvatinib (Cmax and AUC) increased in direct proportion to the administered dose over the range of 3.2 to 32 mg once-daily. 
Pri bolnikih s čvrstimi tumorji, ki so prejeli enkratne in večkratne odmerke lenvatiniba enkrat na dan, se je izpostavljenost lenvatinibu (Cmax in AUC) zvečala neposredno sorazmerno danemu odmerku v območju od 3,2 do 32 mg enkrat na dan.
Estimated using the Kaplan-Meier method; the 95% CI was constructed with a generalised Brookmeyer and Crowley method in patients with a best overall response of complete response or partial response. 
Ocenjeno s Kaplan-Meierjevo metodo; 95-odstotni IZ je bil sestavljen s posplošeno Brookmeyer-Crowleyevo metodo pri bolnikih z najboljšim celotnim odzivom v obliki popolnega odziva ali delnega odziva.
The median time to onset was 26 days. 
Mediani čas do nastopa je bil 26 dni.
Hypertension includes: hypertension, hypertensive crisis, increased diastolic blood pressure , , orthostatic hypertension, and increased blood pressure. 
Hipertenzija vključuje: hipertenzijo, hipertenzivno krizo, zvišanje diastoličnega krvnega tlaka, ortostatsko hipertenzijo in zvišanje krvnega tlaka.
Table 4 Recommended management of hypertension 
Preglednica 4 Priporočila za zdravljenje hipertenzije
Mild to moderate adverse reactions (e.g., Grade 1 or 2) generally do not warrant interruption of lenvatinib, unless intolerable to the patient despite optimal management. 
Blagi do zmerni neželeni učinki (npr. stopnje 1 ali 2) na splošno ne upravičijo prekinitve odmerjanja lenvatiniba, razen če jih bolnik ne more prenašati kljub optimalni obravnavi.
There was no statistically significant difference in overall survival between the treatment groups at the time of the primary efficacy analysis (HR=0.73; 95% CI: 0.50, 1.07, p=0.1032). 
Ni bilo statistično značilne razlike v celotnem preživetju med skupinama z različnima zdravljenjema v času analize primarne učinkovitosti (HR (hazard ratio; razmerje tveganja)=0,73; 95 % IZ: 0,50; 1,07, p=0,1032).
Radioiodine-refractory was defined as one or more measurable lesions either with a lack of iodine uptake or with progression in spite of radioactive-iodine (RAI) therapy, or having a cumulative activity of RAI of >600 mCi or 22 GBq with the last dose at least 6 months prior to study entry. 
Odpornost proti radioaktivnemu jodu je bila opredeljena kot ena ali več merljivih lezij bodisi brez privzema joda bodisi z napredovanjem bolezni kljub zdravljenju z radioaktivnim jodom (RAI) ali s kumulativno aktivnostjo RAI > 600 mCi ali 22 GBq z zadnjim odmerkom vsaj 6 mesecev pred vključitvijo v študijo.
Men had a higher incidence (26.5%) of dysphonia than women (12.3%), decreased weight and decreased platelet count. 
Moški pa so imeli večje incidenco (26,5 %) hripavosti kot ženske (12,3 %), hujšanja in zmanjšanja števila trombocitov.
Similar adverse reactions were observed in clinical trials in DTC and HCC. 
Neželeni učinki, ugotovljeni v kliničnih preskušanjih pri DTC in HCC, so bili podobni.
BP should be monitored after 1 week of treatment with lenvatinib, then every 2 weeks for the first 2 months, and monthly thereafter. 
KT je treba spremljati po 1 tednu zdravljenja z lenvatinibom, nato prva 2 meseca vsaka 2 tedna in zatem enkrat na mesec.
• feeling very tired or weak 
• močna utrujenost ali šibkost,
When systolic BP ≤150 mmHg, diastolic BP ≤95 mmHg, and patient has been on a stable dose of antihypertensive therapy for at least 48 hours, resume lenvatinib at a reduced dose (see section 4.2) 
Ko je sistolični KT ≤ 150 mmHg, diastolični KT ≤ 95 mmHg, bolnik pa je že vsaj 48 ur na stabilnem odmerku antihipertenzivne terapije, spet začnite dajati lenvatinib v zmanjšanem odmerku (glejte poglavje 4.2).
m: Hepatocellular damage and hepatitis includes: drug-induced liver injury, hepatic steatosis, and cholestatic liver injury. 
m: Hepatocelularna poškodba in hepatitis vključujeta: z zdravili povzročeno poškodbo jeter, steatozo jeter in holestatično poškodbo jeter.
Reversibility of the toxicologic changes was observed at the end of a 4-week recovery period in all animal species investigated. 
Pri vseh raziskovanih živalskih vrstah so opazili reverzibilnost toksikoloških sprememb ob koncu 4-tedenskega obdobja okrevanja.
Hypocalcaemia (see section 4.4, QT interval prolongation) 
Hipokalciemija (glejte poglavje 4.4 Podaljšanje intervala QT)
The Rac in HCC subjects with mild and moderate liver impairment was similar to that reported for other solid tumours. 
Vrednost Rac pri bolnikih s HCC z blago in zmerno okvaro jeter je bila podobna vrednosti, ki je bila opisan pri drugih čvrstih tumorjih.
Not adjusted for crossover effect. 
Brez popravka za učinek prehoda.
CI, confidence interval; NE, not estimable; OS, overall survival; PFS, progression-free survival; RPSFT, rank preserving structural failure time model; VEGF/VEGFR, vascular endothelial growth factor / vascular endothelial growth factor receptor. 
IZ, interval zaupanja; NE, ni bilo mogoče oceniti; OS, celotno preživetje; PFS, preživetje brez napredovanja bolezni; RPSFT, model ohranjanja ranga strukturnih napak glede na čas; VEGF/VEGFR, rastni faktor vaskularnega endotelija/receptor za rastni faktor vaskularnega endotelija.
Blood Pressure (BP) level 
Raven krvnega tlaka (KT)
Stratified by region (Region 1: Asia-Pacific; Region 2: Western), macroscopic portal vein invasion or extrahepatic spread or both (yes, no), ECOG PS (0, 1) and body weight (<60 kg, ≥60 kg). 
b Stratificirano po regijah (regija 1: Azija-Pacifik; regija 2: zahodna), makroskopski invaziji portalne vene ali razširjenosti izven jeter ali oboje (da, ne), ECOG PS (0, 1) in telesni masi
• drowsiness, confusion, poor concentration, loss of consciousness that may be signs of liver failure 
• utrujenost, zmedenost, slaba koncentracija, izguba zavesti, ki so lahko znaki težav jetrne odpovedi,
There was a higher incidence of decreased neutrophil count in patients with HCC (8.7% on lenvatinib than in other nonHCC tumour types (1.4%)), which was not associated with infection, sepsis or bacterial peritonitis. 
Pri bolnikih s HCC je bila večja pojavnost zmanjšanega števila nevtrofilcev (8,7 % pri lenvatinibu v primerjavi z drugimi tipi tumorjev brez HCC (1,4 %)), ki ni bila povezana z okužbo, sepso ali bakterijskim peritonitisom.
If you are not sure talk to your doctor before taking LENVIMA. 
Če ste negotovi, se posvetujte z zdravnikom, preden začnete jemati zdravilo LENVIMA.
However, in vivo data indicated that non-P450-mediated pathways contributed to a significant portion of the overall metabolism of lenvatinib. 
Vendar so podatki in vivo pokazali, da so presnovne poti, ki ne potekajo preko citokroma P450, prispevale k pomembnemu deležu celotne presnove lenvatiniba.
Because it is not known if LENVIMA can reduce the effect of the oral contraceptive pill, if this is your normal method of contraception you should ensure you also add a barrier method such as the cap or condoms if you have sex during treatment with LENVIMA. 
Ker ni znano, ali zdravilo LENVIMA lahko zmanjša učinek peroralnih kontracepcijskih tablet, morate v primeru, če je to vaša normalna metoda kontracepcije, zagotoviti, da boste dodatno uporabljali še eno od pregradnih metod kontracepcije, npr. diafragmo ali kondome, če med zdravljenjem z zdravilom LENVIMA spolno občujete.
Lenvatinib is not a substrate for OAT1, OAT3, OATP1B1, OATP1B3, OCT1, OCT2, MATE1, MATE2-K or the bile salt export pump BSEP. 
Lenvatinib ni substrat za OAT1, OAT3, OATP1B1, OATP1B3, OCT1, OCT2, MATE1, MATE2-K ali izločevalno črpalko žolčnih soli BSEP.
Following independent review confirmation of disease progression, 109 (83.2%) patients randomised to placebo had crossed over to open-label lenvatinib at the time of the primary efficacy analysis. 
Po potrditvi napredovanja bolezni z neodvisnim pregledom je 109 bolnikov (83,2 %), randomiziranih na placebo, v času primarne analize učinkovitosti prešlo na odprti lenvatinib.
• yellow skin or yellowing of the whites of the eyes (jaundice) or drowsiness, confusion, poor concentration - these may be signs of liver problems. 
• rumena koža ali porumenelost beločnic (zlatenica) ali zaspanost, zmedenost, slaba koncentracija - to so lahko znaki težav z jetri;